VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com

Posted by Thomas Dobrow on Apr 19th, 2024

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX – Free Report) in a research report released on Thursday morning. The brokerage issued a sell rating on the stock.

Separately, Cantor Fitzgerald reiterated an overweight rating and issued a $2.50 price target on shares of VolitionRx in a report on Wednesday, March 27th.

View Our Latest Research Report on VNRX

VolitionRx Stock Up 3.9 %

NYSE:VNRX opened at $0.62 on Thursday. VolitionRx has a 1 year low of $0.55 and a 1 year high of $2.10. The business has a 50 day simple moving average of $0.88 and a 200-day simple moving average of $0.84.

VolitionRx (NYSE:VNRX – Get Free Report) last posted its quarterly earnings data on Monday, March 25th. The company reported ($0.11) earnings per share (EPS) for the quarter. The firm had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.50 million. Research analysts anticipate that VolitionRx will post -0.4 EPS for the current fiscal year.

Institutional Investors Weigh In On VolitionRx

An institutional investor recently bought a new position in VolitionRx stock. Silverberg Bernstein Capital Management LLC acquired a new position in shares of VolitionRx Limited (NYSE:VNRX – Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned 0.19% of VolitionRx as of its most recent SEC filing. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Company Profile

(Get Free Report)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.